Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis
Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the best biotech stocks to invest in now.
Blueprint Medicines Corp (BPMC)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | PDT Partners Peter Muller | 0 | $0 | 0% | |
| 2. | Schonfeld Strategic Advisors Ryan Tolkin (Cio) | 0 | $0 | 0% | |
| 3. | AQR Capital Management Cliff Asness | 0 | $0 | 0% | |
| 4. | Pentwater Capital Management Matthew Halbower | 0 | $0 | 0% | |
| 5. | TIG Advisors Carl Tiedemann And Michael Tiedemann | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.98 | 1,100 | $48,378.00 | 92,281 | 2022-11-03 | Filing | |
| $82.66 | 10 | $826.60 | 5,822 | 2021-07-13 | Filing | |
| $59.98 | 5,000 | $299,900.00 | 10,812 | 2022-03-03 | Filing | |
| $18.00 | 125,000 | $2,250,000.00 | 2,500,711 | 2015-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $128.25 | 1,172 | $150,309.00 | 63,546 | 2025-07-03 | Filing | |
| $128.25 | 1,051 | $134,790.75 | 53,155 | 2025-07-03 | Filing | |
| $127.88 | 2,418 | $309,213.84 | 54,206 | 2025-06-03 | Filing | |
| $127.88 | 241 | $30,819.08 | 56,624 | 2025-06-03 | Filing | |
| $101.93 | 650 | $66,254.50 | 146,630 | 2025-05-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 66 | $8,544 | 0% | |
| 2. | 23 | $2,946 | 0% | |
| 3. | 25,883 | $2,548 | 0% | |
| 4. | 1 | $129 | 0% | |
| 5. | 132 | $17 | 0% |
News See All
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform
On June 3, Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform without a price target.
Stephens & Co. Downgrades Blueprint Medicines (BPMC) to Equal Weight, Cuts PT
On June 3, Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from Overweight, slashing the price target to $135 from $150.
Blueprint Medicines Corporation (BPMC) Downgraded at TD Cowen
This modification comes after Sanofi declared its intention to buy Blueprint Medicines Corporation (NASDAQ:BPMC).
Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform
This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in contingent value rights.
Why Blueprint Medicines Corporation (BPMC) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript May 1, 2025Blueprint Medicines Corporation misses on earnings expectations.
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Hedge Fund Resource Center Billionaire Hedge Funds
